Cardiovascular Disease
Receive up to $2,870 in compensation for participation.
A study of inclisiran to prevent cardiovascular events in high-risk primary prevention patients.
Qualified Participants:
- Age 40-79
- At an increased risk for first major adverse cardiovascular event
